BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tomazos I, Sierra JR, Johnston KM, Cheung A, Brodsky RA, Weitz IC. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab. Hematology 2020;25:327-34. [PMID: 32856539 DOI: 10.1080/16078454.2020.1807226] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Cannas G, Dubreuil L, Fichez A, Gerfaud-Valentin M, Debard AL, Hot A. Delayed Severe Hemolytic Transfusion Reaction During Pregnancy in a Woman with β-Thalassemia Intermediate: Successful Outcome After Eculizumab Administration. Am J Case Rep 2021;22:e931107. [PMID: 33983909 DOI: 10.12659/AJCR.931107] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Yoo JJ, Chonat S. Evaluating ravulizumab for the treatment of children and adolescents with paroxysmal nocturnal hemoglobinuria. Expert Rev Hematol 2022. [PMID: 35502699 DOI: 10.1080/17474086.2022.2073215] [Reference Citation Analysis]
3 Cheng WY, Sarda SP, Mody-Patel N, Krishnan S, Yenikomshian M, Mahendran M, Lejeune D, Yu LH, Duh MS. Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population. Adv Ther 2021;38:4461-79. [PMID: 34275086 DOI: 10.1007/s12325-021-01825-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]